The present invention relates, in general terms, to methods of reducing the formation of post-surgery tissue adhesion in a subject in need thereof by administering an adhesion barrier composition. The present invention also relates to methods of preventing the formation of tissue adhesion during or post-surgery in a subject in need thereof. The adhesion barrier composition comprises sporopollenin and a biodegradable polymer. The present invention also relates to methods of fabricating the adhesion barrier composition.

The present invention relates, in general terms, to methods of reducing the formation of post-surgery tissue adhesion in a subject in need thereof by administering an adhesion barrier composition. The present invention also relates to methods of preventing the formation of tissue adhesion during or post-surgery in a subject in need thereof. The adhesion barrier composition comprises sporopollenin and a biodegradable polymer. The present invention also relates to methods of fabricating the adhesion barrier composition.

The present invention provides methods treating multiple sclerosis (MS) in a patient in need of treatment thereof. The methods comprise co-administering to the patient a fumarate or pharmaceutical acceptable salt thereof, and at least one sulfonylurea or pharmaceutical acceptable salt thereof, where the amount of the fumarate is administered at a dose lower than the therapeutically effective dose if the fumarate is administered alone.

The present invention provides methods treating multiple sclerosis (MS) in a patient in need of treatment thereof. The methods comprise co-administering to the patient a fumarate or pharmaceutical acceptable salt thereof, and at least one sulfonylurea or pharmaceutical acceptable salt thereof, where the amount of the fumarate is administered at a dose lower than the therapeutically effective dose if the fumarate is administered alone.

The present invention provides methods treating multiple sclerosis (MS) in a patient in need of treatment thereof. The methods comprise co-administering to the patient a fumarate or pharmaceutical acceptable salt thereof, and at least one sulfonylurea or pharmaceutical acceptable salt thereof, where the amount of the fumarate is administered at a dose lower than the therapeutically effective dose if the fumarate is administered alone.

The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.

The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.

The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum producing tissue.

The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum producing tissue.

The present invention relates to injectable pharmaceutical compositions comprising therapeutically effective amount of succinylcholine chloride, one or more pharmaceutically acceptable aqueous solvents, and one or more stabilizing agents selected from aliphatic polyols; lower alkyl alcohols; amino acids having at least one additional amino, carboxyl or hydroxyl group; amino alcohols; and aliphatic dicarboxylic acids having at least one hydroxyl or amino group, or α-β unsaturation. The compositions are stable at room temperature for at least 30 days. Methods of manufacturing the injectable pharmaceutical compositions are also provided. The composition may be provided in a sealed container, e.g., an ampoule, vial and pre-filled syringe, and are suitable for subcutaneous, intravenous or intramuscular administration as an adjunct to general anesthesia, to facilitate tracheal intubation, and/or to provide skeletal muscle relaxation during surgery or mechanical ventilation.